Friday, 20 February 2026 BB Biotech FY 2025 results release   — FY 2025 analyst conference call: 20 February 2026 at 10.00am CET –  [join Webscast]

Friday, 20 February 2026 BB Biotech FY 2025 results release   — FY 2025 analyst conference call: 20 February 2026 at 10.00am CET –  [join Webscast]

Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Edison Investment Research notes that despite macroeconomic uncertainty and heightened market volatility, BB Biotech’s portfolio companies continue to deliver on clinical and regulatory milestones. According to Edison, BB Biotech has responded proactively by consolidating its portfolio, increasing exposure to high-quality, larger-cap names, and enhancing risk management - positioning the investment company to capture long-term biotech growth at compelling valuations.

BB Biotech: staying the course amid market volatility

Edison Investment Research notes that despite macroeconomic uncertainty and heightened market volatility, BB Biotech’s portfolio companies continue to deliver on clinical and regulatory milestones. According to Edison, BB Biotech has responded proactively by consolidating its portfolio, increasing exposure to high-quality, larger-cap names, and enhancing risk management - positioning the investment company to capture long-term biotech growth at compelling valuations.
26.05.2025